constructed fibronectin-targeted nanoparticles (CREKA-ICG-LIP NPs) by co-assembling fibronectin-targeting peptide (CREKA) and ICG and used them for enhanced PAI to detect infarcted areas noninvasively and help diagnose MI.115. The gene discussed is FN1; the disease is myocardial infarction.